



ALEXION CANADA INDUSTRIAL PHARMACY RESIDENCY PROGRAM

Medical Affairs – Hematology and Nephrology

Alexion Canada is pleased to offer a one-year residency in partnership with the Leslie Dan Faculty of Pharmacy, University of Toronto. This residency is ideal for recent graduates in pharmacy programs with a career interest in Medical Affairs with a focus in the therapeutic areas of hematology and nephrology, and in the ultra-rare diseases space. The successful candidate will be a highly proficient and self-directed learner with a keen interest in working with a pharmaceutical company within a medical role.

Medical Affairs is the department responsible for subject matter expertise and proactively/reactively provides medical, scientific, strategic and functional expertise to the hematology and nephrology teams at the brand level. Work with cross-functional colleagues involves defining, creating and implementing strategic medical plans, participating in the development of key messages and labels, reviewing promotional and informational materials, developing or reviewing slide decks as needed, and supporting the updating of such communication and educational plans as well as related tools/resources. The function also supports the regulatory affairs team by providing medical and scientific input and review for product submissions and responses, helping to develop and update regulatory documents, and participating in meetings with regulatory agencies (i.e. Health Canada), where appropriate. The justification of regulatory claims is based on critical review and analysis of global documents and literature. The medical function also works closely with the market access team in the development of submissions and presentations for payers/HTA groups/hospitals/institutional formulary committees.

As an industrial pharmacy resident, the objective of the program is to develop and hone competencies in several of the aforementioned areas through day-to-day responsibilities within medical affairs. The pharmacy resident will also have the opportunity to explore other functions including marketing, regulatory affairs, and market access during the course of the residency term, through ongoing interactions with these functions, and potentially through projects, as availability in the company permits.

KEY RESPONSIBILITIES

- Meaningfully contribute to the national scientific/medical activities through the assistance in the development and execution of said initiatives. Note that responsibilities will vary depending on the functional area needs:
 - Assist the cross-functional team on projects/tasks focusing on currently marketed and pipeline assets;
 - Prepare summaries of scientific data, study protocols, meeting abstracts, and evaluation and critical appraisal of scientific literature;
 - Assist with the organization of advisory boards/consultant meetings, internal/external scientific training and educational events;
 - Assist with the execution of strategies for the purpose of establishing the role of Canadian diagnostic and genetic testing and treatment guidelines;

- Develop and update internal and external presentations as they relate to medical communication, education, sales training, etc.;
- Assist in the development of submissions to HTA bodies, payers, and regulatory agencies, including clinical summaries, budget impact analyses, cost-effectiveness studies, and other such reports/analyses;
- Formulate strategy to address internal and external requests as required to develop standard responses / FAQ packages to medical information inquiries from health care professionals
- Administrative support for the medical function including but not limited development of agenda, organizing cross-functional and/or departmental meetings, calendar invitations, etc.

ABOUT ALEXION

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.

Applications and further information about the Industrial Pharmacy Residency Program can be Obtained by contacting:

c/o Leslie Dan Faculty of Pharmacy

University of Toronto

144 College Street

Toronto, ON M5S 3M2

Email: pharm.residency@utoronto.ca

Website: www.pharmacy.utoronto.ca/residency-programs/industrial-pharmacy

Interviews begin in the fall for the next academic year